|
Characteristic/category
|
Number examined
|
Number positive (%)
|
Bivariate analysis
|
Multivariate analysis
|
GMPD (range)
|
Statistic
|
P-value
|
|---|
|
OR (95 % CI)
|
P-value$
|
OR (95 % CI)
|
P-value£
|
|---|
|
Age Group (years)
|
|
< 5
|
66
|
16 (24.2)
|
1.67 (0.62–4.12)
|
0.455
|
1.02 (0.28–3.71)
|
0.976
|
633.0 (80–24000)
|
H = 3.406
|
0.18
|
|
5–10
|
120
|
34 (28.3)
|
1.97 (0.84–4.67)
|
0.167
|
3.05 (1.11–8,42)
|
0.031*
|
234.0 (40–24000)
| | |
|
11–15
|
48
|
8 (16.7)
|
Reference
| | | |
463.3 (40–16000)
| | |
|
Sex
|
|
Males
|
96
|
14 (14.6)
|
Reference
| | | |
549.0 (40–2400)
|
U = 218.0
|
0.10
|
|
Females
|
138
|
44 (31.9)
|
2.74 (1.40–5.36)
|
0.004*
|
3.08 (1.37–6.93)
|
0.007*
|
290.0 (40–24000)
| | |
|
Fever
|
|
Yes
|
14
|
4 (28.6)
|
1.23 (0.37–4.08)
|
0.985
|
1.38 (0.24–7.88)
|
0.716
|
3098.4 (400–24000)
|
U = 34.00
|
0.02*
|
|
No
|
220
|
54 (24.5)
|
Reference
| | | |
287.3 (40–2400)
| | |
|
CD4 T cell (cells/μl of blood)
|
|
< 200
|
28
|
8 (28.6)
|
1.20 (0.49–2.96)
|
0.873
|
1.80 (0.55–5.85)
|
0.33
|
82.4 (40–360)
|
H = 11.598
|
0.003*
|
|
200–499
|
44
|
12 (27.3)
|
1.07 (0.37–3.06)
|
0.881
|
1.20 (0.46–3.13)
|
0.70
|
405.2 (80–16000)
| | |
|
≥ 500
|
144
|
36 (25.0)
|
Reference
| | | |
491.3 (40–24000)
| | |
|
Clinical stages
|
|
Stage 1
|
44
|
16 (36.4)
|
4.29 (1.28–14.4)
|
0,027*
|
10.38 (2.43–44.46)
|
0.0016*
|
191.2 (40–5040)
|
H = 14.36
|
0.002*
|
|
Stage 2
|
62
|
10 (16.1)
|
1.44 (0.42–5.00)
|
0.782
|
1.46 (0.36–5.87)
|
0.59
|
512.2 (40–5400)
| | |
|
Stage 3
|
82
|
24 (29.3)
|
3.10 (0.99–9.77)
|
0.077
|
2.62 (0.76–9.09)
|
0.13
|
498.4 (80–2400)
| | |
|
Stage 4
|
34
|
4 (11.8)
|
Reference
| | | |
40.0 (40–40)
| | |
|
Use of ART
|
|
Yes
|
182
|
52 (28.6)
|
Reference
| | | |
314.8 (40–24000)
|
U = 136.00
|
0.62
|
|
No
|
52
|
6 (11.5)
|
3.07 (1.24–7.61)
|
0.019*
|
0.194 (0.06–0.62)
|
0.0001*
|
635.0 (40–16000)
| | |
- OR Odds Ratio, *Statistically significant, CI Confidence Interval, $:Estimated by Yates adjusted Chi-Square, £:Estimated by Multiple Logistic Regression
